摘要
探讨从原发性肝癌(hepatocellular carcinoma,HCC)患者的术后肿瘤组织中分离肿瘤浸润性淋巴细胞(tumor-infiltrating lymphocyte,TIL),并进行体外大量扩增的方法。在该研究工作中,组织标本来源于术后的肿瘤癌旁组织,经过组织破碎、酶消化后,采用不连续密度梯度离心分离其中淋巴细胞。分离的淋巴细胞先采用大剂量重组人白介素2(IL-2)(2 000 U/mL)进行引发,然后采用同种异体的外周血单核细胞作为饲养细胞进行扩增。针对9例原发性肝癌术后标本,所分离的TIL均能成功进行培养扩增,扩增后细胞数为(1~5.5)×10^9。扩增倍数为111~572。扩增后的TIL,表型检测发现CD3+细胞的比例为(90.3±9.4)%,CD3+CD4+细胞的比例为(24.9±14.1)%,CD3+CD8+细胞的比例为(56.4±20.2)%,CD3+CD56+细胞的比例为(14.8±12.6)%。杀伤检测结果显示,肝癌TIL对非自体肿瘤细胞系HepG2和Bel-7402有较强的杀伤作用。因此,采用该改良的方法,原发性肝癌的TIL在体外可以成功进行培养扩增,并具有较强抗肿瘤活性,可以作为肝癌术后巩固性免疫治疗的一种手段。
The aim was to investigate the methods of ex vivo expansion of tumor-infiltrating lymphocyte (TIL) obtained from hepatocellular carcinoma (HCC) biopsy specimens with a rapid expansion protocol. In this study, the specimen of primary liver cancer came from adjacent carcinoma tissues. After crushing and enzymatic digestion, the lymphocytes in the single-cell slurry were separated by density centrifugation. The isolated lymphocytes were triggered with high dose of recombinant human interleukin 2 (IL-2) (2 000 U/mL), then were expanded in large-scale using peripheral blood allogeneic mononuclear cells as feeder cells. Nine primary HCC samples were used to try to isolate and culture the TIL in vitro. After two-step culturing, the number of TIL could achieve (1.0-5.5)×10^9 cells, and the expansion fold was 111 to 572. After expansion, the ratio of CD3+ T cells was (90.3±9.4)%, the ratio of CD3+CD4+ T cells was (24.9±14.1)%, the ratio of CD3+CD8+ was (56.4±20.2)%, and the ratio of CD3+CD56+ was (14.8±12.6)%. Moreover, the TIL showed strong killing activity to HepG2 and Bel-7402 cell lines in vitro. Taken together, the TIL from hepatocellular carcinoma can be successfully cultured and expanded in vitro, and with strong anti-tumor activity. It can be served as a means of the candidate immunotherapy for postoperative HCC patients.
出处
《中国细胞生物学学报》
CAS
CSCD
北大核心
2014年第7期970-975,共6页
Chinese Journal of Cell Biology
基金
广东省自然科学基金(批准号:2011A030400004)资助的课题~~
关键词
肝癌
肿瘤浸润性淋巴细胞
免疫治疗
体外扩增培养
hepatocellular carcinoma
tumor-infiltrating lymphocyte
immunotherapy
ex-vivo expansionculture